BG
PRME icon

Bollard Group’s Prime Medicine PRME Stock Holding History

Bollard Group’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.26M Hold
361,136
– – 0.04% 102
2025
Q4 		$1.25M Hold
361,136
– – 0.03% 101
2025
Q3 		$2M Hold
361,136
– – 0.05% 90
2025
Q2 		$892K Hold
361,136
– – 0.02% 124
2025
Q1 		$719K Hold
361,136
– – 0.02% 121
2024
Q4 		$1.05M Hold
361,136
– – 0.03% 104
2024
Q3 		$1.4M Hold
361,136
– – 0.04% 107
2024
Q2 		$1.86M Hold
361,136
– – 0.05% 85
2024
Q1 		$2.53M Hold
361,136
– – 0.08% 74
2023
Q4 		$3.2M Buy
+361,136
New +$2.78M 0.11% 63

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Bollard Group's PRME Position: Q1 2026 in Review

Bollard Group held its Prime Medicine (PRME) position steady in Q1 2026 at 361,136 shares worth $1.26M. The position accounts for 0.04% of the portfolio, ranked #102.

Bollard Group first reported a position in PRME in Q4 2023 and has held it in 10 quarters since. The position peaked at $3.2M in Q4 2023. 192 funds tracked by Wall St. Rank hold PRME as of Q1 2026.

  • Bollard Group held 361,136 shares of Prime Medicine worth $1.26M as of Q1 2026.
  • Bollard Group left its Prime Medicine share count unchanged in Q1 2026.
  • Prime Medicine made up 0.04% of Bollard Group's portfolio in Q1 2026, its #102 holding.
  • Bollard Group first reported a position in Prime Medicine in Q4 2023 and has held it in 10 quarters since.
  • Bollard Group's Prime Medicine position peaked at $3.2M in Q4 2023.
  • 192 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2026.

Based on Bollard Group's 13F filing for Q1 2026, filed 14 May 2026.